Agilent Technologies, Inc.
AHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeAgilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. At a $48.79B market cap, Agilent Technologies, Inc. ranks as a large-cap company within healthcare. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Market Cap
$48.79B
Beta
1.21
P/E (TTM)
34.14
P/E (Fwd)
25.70
EPS (TTM)
$5.07
EPS (Fwd)
$6.73
ROE
21.0%
ROA
8.6%
Cash
$1.76B
Total Debt
$4.15B
Free CF
$1.06B
52W Change
16.9%
Annual Financials
Cash vs Debt
Where A stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, A finished 27.73% above its 150-day moving average ($133.52) and 28.06% above its 200-day moving average ($133.17). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is A overbought or oversold?
At the October 12, 2026 close, A's RSI(14) was 62.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, A has $1.76B in cash with $4.15B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $1.06B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 21.0%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $6.85B (2022) to $6.95B (2025).
As with any equity investment, A carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing A.